{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T20:40:31Z","timestamp":1785444031622,"version":"3.56.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.ijid.2022.05.057","type":"journal-article","created":{"date-parts":[[2022,5,28]],"date-time":"2022-05-28T15:35:31Z","timestamp":1653752131000},"page":"230-236","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus"],"prefix":"10.1016","volume":"122","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6058-5686","authenticated-orcid":false,"given":"Cheng-En","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Jui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Chung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann-Tay","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang-Huei","family":"Sheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yee-Chun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shan-Chwen","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijid.2022.05.057_bib0001","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1093\/jac\/dkh350","article-title":"Vancomycin-induced deletion of the methicillin resistance gene mecA in Staphylococcus aureus","volume":"54","author":"Adhikari","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0002","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.jksus.2018.07.018","article-title":"Molecular typing of MRSA isolates by spa and PFGE","volume":"31","author":"Alkharsah","year":"2019","journal-title":"J King Saud Univ Sci"},{"key":"10.1016\/j.ijid.2022.05.057_bib0003","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1093\/jac\/dku114","article-title":"Analysis of Staphylococcus aureus clinical isolates with reduced susceptibility to ceftaroline: an epidemiological and structural perspective","volume":"69","author":"Alm","year":"2014","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0004","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1099\/jmm.0.000566","article-title":"Detection of high levels of resistance to linezolid and vancomycin in Staphylococcus aureus","volume":"66","author":"Azhar","year":"2017","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijid.2022.05.057_bib0005","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1749-6632.2012.06819.x","article-title":"Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall","volume":"1277","author":"Bayer","year":"2013","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ijid.2022.05.057_bib0006","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/S1473-3099(13)70136-1","article-title":"Molecular epidemiology of community-associated meticillin-resistant Staphylococcus aureus in Asia","volume":"13","author":"Chuang","year":"2013","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.ijid.2022.05.057_bib0007","series-title":"Performance standards for antimicrobial susceptibility testing: 30th informational supplement, M100S","year":"2020"},{"key":"10.1016\/j.ijid.2022.05.057_bib0008","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofx084","article-title":"Ceftaroline for severe methicillin-resistant Staphylococcus aureus infections: a systematic review","volume":"4","author":"Cosimi","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.ijid.2022.05.057_bib0009","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1055\/s-0034-1396906","article-title":"Combination antibiotic treatment of serious methicillin-resistant Staphylococcus aureus infections","volume":"36","author":"Davis","year":"2015","journal-title":"Semin Respir Crit Care Med"},{"key":"10.1016\/j.ijid.2022.05.057_bib0010","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1093\/cid\/cir340","article-title":"Use of antistaphylococcal beta-lactams to increase daptomycin activity in eradicating persistent bacteremia due to methicillin-resistant Staphylococcus aureus: role of enhanced daptomycin binding","volume":"53","author":"Dhand","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.05.057_bib0011","doi-asserted-by":"crossref","first-page":"2933","DOI":"10.1128\/AAC.00330-12","article-title":"Summary of ceftaroline activity against pathogens in the United States, 2010: report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program","volume":"56","author":"Flamm","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0012","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1099\/jmm.0.000341","article-title":"In vitro ceftaroline combinations against meticillin-resistant Staphylococcus aureus","volume":"65","author":"Garc\u00eda","year":"2016","journal-title":"J Med Microbiol"},{"key":"10.1016\/j.ijid.2022.05.057_bib0013","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1172\/JCI68834","article-title":"Mechanisms of vancomycin resistance in Staphylococcus aureus","volume":"124","author":"Gardete","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.ijid.2022.05.057_bib0014","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eimc.2019.03.007","article-title":"In vitro activity of ceftaroline in combination with other antimicrobials active against Staphylococcus spp","volume":"38","author":"Gil Romero","year":"2020","journal-title":"Enferm Infecc Microbiol Clin (Engl)"},{"key":"10.1016\/j.ijid.2022.05.057_bib0015","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1186\/s13054-017-1801-3","article-title":"Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment","volume":"21","author":"Hassoun","year":"2017","journal-title":"Crit Care"},{"key":"10.1016\/j.ijid.2022.05.057_bib0016","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkx349","article-title":"Daptomycin","volume":"73","author":"Heidary","year":"2018","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0017","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.idc.2016.02.009","article-title":"Bacteremia due to methicillin-resistant Staphylococcus aureus: new therapeutic approaches","volume":"30","author":"Holubar","year":"2016","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.ijid.2022.05.057_bib0018","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.jmii.2020.04.017","article-title":"In vitro susceptibility of ceftaroline against clinically important Gram-positive cocci, Haemophilus species and Klebsiella pneumoniae in Taiwan: results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) in 2012\u20132018","volume":"54","author":"Jean","year":"2021","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.ijid.2022.05.057_bib0019","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/jac\/dkaa543","article-title":"Effective antimicrobial combination in vivo treatment predicted with microcalorimetry screening","volume":"76","author":"Kragh","year":"2021","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0020","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijid.2022.05.057_bib0021","first-page":"269","article-title":"Vancomycin resistance in Staphylococcus aureus","volume":"90","author":"McGuinness","year":"2017","journal-title":"Yale J Biol Med"},{"key":"10.1016\/j.ijid.2022.05.057_bib0022","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a026997","article-title":"Mechanism of action and resistance to daptomycin in Staphylococcus aureus and enterococci","volume":"6","author":"Miller","year":"2016","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.ijid.2022.05.057_bib0023","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1128\/AAC.02463-14","article-title":"Antagonism between bacteriostatic and bactericidal antibiotics is prevalent","volume":"58","author":"Ocampo","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jac\/dkg301","article-title":"Synergy, antagonism, and what the chequerboard puts between them","volume":"52","author":"Odds","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drup.2013.10.002","article-title":"Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the \"seesaw effect\": taking advantage of the back door left open?","volume":"16","author":"Ortwine","year":"2013","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ijid.2022.05.057_bib0026","doi-asserted-by":"crossref","first-page":"6154","DOI":"10.1038\/s41598-017-06329-2","article-title":"Role of SCCmec type in resistance to the synergistic activity of oxacillin and cefoxitin in MRSA [sci rep]","volume":"7","author":"Reichmann","year":"2017","journal-title":"Sci Rep"},{"key":"10.1016\/j.ijid.2022.05.057_bib0027","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/AAC.00797-12","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","author":"Rose","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0028","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"10.1016\/j.ijid.2022.05.057_bib0029","series-title":"Effect of beta-lactam (BL) exposure in vitro on daptomycin (DAP) activity and cell wall thickness in MRSA, poster E-1332 Annu Intersci conference Antimicrob Agents Chemother (ICAAC)","author":"Sakoulas","year":"2011"},{"key":"10.1016\/j.ijid.2022.05.057_bib0030","first-page":"e66445","article-title":"Detection of synergistic antimicrobial activities of ceftaroline, telavancin, daptomycin, and vancomycin against methicillin-resistant Staphylococcus aureus strains in intensive care units","volume":"In","author":"\u015eanal","year":"2018","journal-title":"Jundishapur J Microbiol"},{"key":"10.1016\/j.ijid.2022.05.057_bib0031","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1080\/23744235.2016.1277587","article-title":"A combination of ceftaroline and daptomycin has synergistic and bactericidal activity in vitro against daptomycin nonsusceptible methicillin-resistant Staphylococcus aureus (MRSA)","volume":"49","author":"Shafiq","year":"2017","journal-title":"Infect Dis (Lond)"},{"key":"10.1016\/j.ijid.2022.05.057_bib0032","doi-asserted-by":"crossref","first-page":"4678","DOI":"10.1128\/AAC.00497-10","article-title":"Synergy testing by Etest, microdilution checkerboard, and time-kill methods for pan-drug-resistant Acinetobacter baumannii","volume":"54","author":"Sopirala","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0033","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1016\/j.bbamem.2006.02.009","article-title":"Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: comparison with cationic antimicrobial peptides and lipopeptides","volume":"1758","author":"Straus","year":"2006","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.ijid.2022.05.057_bib0034","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.ijantimicag.2019.08.012","article-title":"Ceftaroline fosamil as a potential treatment option for Staphylococcus aureus community-acquired pneumonia in adults","volume":"54","author":"Welte","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijid.2022.05.057_bib0035","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0036","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1128\/AAC.02354-12","article-title":"Novel combinations of vancomycin plus ceftaroline or oxacillin against methicillin-resistant vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous VISA","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0037","series-title":"Antimicrobial resistance: global report on surveillance","year":"2014"},{"key":"10.1016\/j.ijid.2022.05.057_bib0038","first-page":"61","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijid.2022.05.057_bib0039","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1016\/j.jmii.2015.02.060","article-title":"Linezolid-resistant MRSA strains sequentially isolated from an elderly patient with pneumonia during prolonged therapy with linezolid","volume":"48","author":"Zhou","year":"2015","journal-title":"J Microbiol Immunol Infect"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222003186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1201971222003186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,5,11]],"date-time":"2024-05-11T14:32:00Z","timestamp":1715437920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1201971222003186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":39,"alternative-id":["S1201971222003186"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2022.05.057","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2022.05.057","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}]}}